Rheumatology Association guidelines indicate that patients should be considered for biologic disease modifying anti-rheumatic drugs (bDMARDs) if moderate to high disease activity [i.e. 28-joint disease activity score (DAS28) > 3.2] persists after 3 months, despite treatment with at least two prior synthetic DMARDs (sDMARDs), such as MTX. 4 Randomized clinical trials (RCTs), including the pivotal RAPID-1 (ClinicalTrials.gov identifier: NCT00152386) and RAPID-2 (ClinicalTrials. gov identifier: NCT00175877) studies, have demonstrated a fast, clinical response in CZPtreated RA patients. 5, 6 However, while RCTs provide important results regarding the efficacy and tolerability of a drug, the selective nature of their design and subsequent under-representation of particular patient demographics may not reflect clinical practice. 7 Several publications have reported on real-world effectiveness and safety of the first anti-TNFs approved for RA. The most recently approved anti-TNFs are under-represented in the current literature; however, the inclusion of data from patients treated with these anti-TNFs within registry reports is increasing. [8] [9] [10] For this reason, real-world evidence studies evaluating the effectiveness of CZP are needed. 11 Real-world, observational studies are particularly useful as they provide data on treatment tolerability and safety in large heterogeneous populations, and show how the clinical setting influences treatment outcomes, and thus complement the data provided in RCTs. 12 Here, we report the largest sample of real-world effectiveness and safety data of CZP treatment, to our knowledge, in patients with RA in a Canadian practice setting from the observational FαsT-CAN trial. This study is also the first to report real-world workplace and household productivity in Canadian patients with RA.
Methods

Patients
Patients aged ⩾18 years with moderate to severe, active RA were enrolled into the study. All patients provided written, informed consent prior to their participation in the study. The decision to initiate CZP treatment was made by the physician prior to their patient's enrolment into the study; all patients were prescribed CZP in line with the Canadian CZP product monograph, during routine clinical practice. 3 Prior biologic use was permitted and enrolled patients could take non-biologic DMARDs concomitantly during the study; all RA medications were prescribed at the discretion of the treating physician.
Any patients who had previously been treated with CZP, or had a known hypersensitivity to CZP, or any of its components, were not permitted to take part in the study. Patients with active tuberculosis or other severe infections such as sepsis, abscesses and opportunistic infections were not eligible for inclusion.
Study design
FαsT-CAN was a prospective, observational, multi-center study conducted between 22 December 2010 and 6 December 2016 at a total of 48 sites in Canada. Patients were observed for a duration of 104 weeks, with an additional 10-week safety follow-up if patients did not prematurely discontinue CZP treatment. No investigational products were used in this study; CZP was provided only upon prescription by the patient's physician. All patient clinical procedures, assessments and decisions were undertaken as decided by the physician in the framework of current standard clinical practice and as directed in the Canadian Cimzia™ Product Monograph. In accordance with the Canadian product monograph for CZP, a loading dose of 400 mg CZP by subcutaneous injection was given at Weeks 0, 2 and 4, followed by a maintenance dose of 200 mg CZP every 2 weeks or 400 mg CZP every 4 weeks. The full analysis set (FAS) consisted of all patients who received ⩾1 dose of CZP, with a baseline DAS28 value and ⩾1 valid post-baseline DAS28 values. The safety set (SS) included all patients who received ⩾1 dose of CZP.
The study was performed in full compliance with the Declaration of Helsinki and was approved by the local or central ethics committees.
Study procedures and evaluations
The primary objective of this study was to assess the clinical effectiveness of CZP in achieving a DAS28 < 2.6 after 2 and years of therapy in adult patients with RA. DAS28 was preferentially assessed using C-reactive protein (CRP); however, if CRP measurements were unavailable erythrocyte sedimentation rate (ESR) was used, providing that the assessment was consistent for that patient for the duration of the study. Post-hoc analyses determined the proportions of patients achieving DAS28(ESR) < 2.6 and ⩽3.2 (i.e. disease remission, and low disease activity) and DAS28(CRP) < 2.6 and ⩽3.2.
The procedures carried out during the study were in accordance with current clinical practice for RA; data were collected during physician visits which corresponded most closely to the study schedule of Weeks 0, 12, 20/24, 76, 104, and 114 (for patients included in the safety follow-up).
Additional study outcomes. Disease activity was measured using the Clinical Disease Activity Index (CDAI) at each study visit. The joint assessment was carried out on 28 joints; if joints were missing or not assessable, the number of joints was weighted by the actual number of evaluated joints.
The Health Assessment Questionnaire-Disability Index (HAQ-DI) was measured at Week 104. The proportion of patients achieving the minimal clinically important differences (MCIDs) in HAQ-DI, defined as a decrease of ⩾0.22 points from baseline, was assessed post-hoc and reported to Week 104. 13, 14 Patients reported the duration of morning stiffness, in minutes, which was defined as the time elapsed between the patient waking and being as limber as would be normal for the patient during a typical day. Patients rated the impact of RA on their fatigue during the past week on the validated Canadian versions of the Fatigue Assessment Scale (0-10 scale), at all timepoints to Week 104. Change from baseline in patients' assessment of arthritis pain (PtAAP) was measured using a visual analogue scale [VAS; 0 (no symptoms), 100 (severe symptoms)]. Patients scored the level of pain caused by arthritis at the time of the visit, using the validated Canadian versions of the questionnaire.
The validated arthritis-specific work productivity survey (WPS-RA) was used to assess the impact of RA on productivity within the household and the workplace, and is reported to Week 104. 15 The number of days of work missed (absenteeism), the number of days with productivity reduced by ⩾50% (presenteeism), and the level of arthritis interference with productivity (0-10 scale; 0 = no interference and 10 = complete interference) were recorded.
Safety analyses. Safety data report treatmentemergent adverse events (TEAEs), including serious adverse events (SAEs), assessed as related to CZP, and adverse events of special interest (serious infections, malignancies, serious hemorrhage and serious skin reactions) irrespective of their relationship to CZP. Other TEAEs (including SAEs), assessed as not related to CZP were also recorded when reported, although their collection was not foreseen in the study protocol or performed systematically, so should be interpreted with caution.
Statistical analyses
Statistical differences in DAS28 were calculated between baseline and Week 12, 20/24, 52, and 104. Student's t-tests were performed Post-hoc; the resulting p values are nominal and should therefore be interpreted in an exploratory nature. The p values have not been provided for secondary outcomes because it would be inappropriate to infer differences when the values would be associated with bias due to an increased level of type I error. The FAS, defined as all patients with a baseline DAS28 ⩾ 2.6, who took ⩾1 dose of CZP and provided ⩾1 valid post-baseline DAS28 measurement, was used for all clinical effectiveness measurements.
Safety analyses were performed on the SS, which included all patients having taken ⩾1 dose of CZP. All TEAEs were classified according to the Medical Dictionary for Regulatory Activities version 19.0. Incidence of TEAEs were reported as the number of first occurrences of an event per 100 patient-years of exposure. The exposure-adjusted event rate (EAER) was reported per 100 patientyears to account for the mean total duration of CZP, and was calculated as:
EAER
Number of adverse events observed Total patient years of expo
Missing binary values were imputed using nonresponder imputation (NRI), while missing continuous values were not imputed. Patients who did not complete the 104 weeks were considered to be non-responder.
Results
Patient disposition and baseline characteristics
A total of 546 patients were enrolled into the study, of which 229/546 (41.9%) completed to Week 104 (Supplementary Figure S1 ). The reasons provided by the treating physician for discontinuation included adverse events (n = 73), lack of efficacy (n = 177), lost to follow-up (n = 28), protocol deviation (n = 1), consent withdrawn (n = 14), and other (n = 22). Table S1 ).
Disease activity
At Week 104, 90/451 (20.0%) patients achieved the primary objective of DAS28 < 2.6. The proportion of patients achieving DAS28 < 2.6 was sustained from Week 12 through Week 104, when data were imputed using the NRI [ Figure 1( Household and workplace productivity At baseline, 187 (41.7%) patients were employed, of whom the majority had a non-manual job. All measures of household and workplace productivity improved at Week 104, despite a high burden of RA on workplace and household productivity at baseline (Figure 3 ).
Safety
The mean duration (SD) of exposure to CZP was 482.0 (292.6) days, with a total exposure of 800.6 patient-years. A total of 279 patients reported 706 TEAEs during the study, of which 162 patients reported 281 TEAEs which were considered as related to CZP treatment ( Table 2 ). The most commonly reported TEAE (occurring in ⩾5% of patients) by MedDRA preferred term was upper respiratory tract infection ( Prior anti-TNFs and biologics a 0.7 ( ⩾2% of patients) were upper respiratory tract infection (14 patients), sinusitis (13 patients) and rash (11 patients), shown in Table 2 .
A total of 76 SAEs were reported during the study. SAEs, which were considered to be related to CZP, were reported by 20 (3.7%) patients. A total of 24 serious treatment-emergent infections were reported by 14 (2.6%) patients, the most commonly reported serious infections by preferred term (occurring in ⩾0.4% of patients) were pneumonia [5 (0.9%) patients] and sepsis [3 (0.5%) patients]. Of these, 14 serious infections, reported by 10 patients, were considered to be related to CZP treatment by the patient's physician. No cases of tuberculosis were observed during the study.
Malignancies were reported in nine (1.6%) patients and included one case each of lymphoma, lung cancer, throat cancer, invasive ductal breast carcinoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma, and two cases of basal cell carcinoma. The case of lymphoma was considered by the patient's physician to be related to CZP, while the remaining eight reported malignancies were not considered to be related to CZP by the patients' physicians.
Overall, five deaths were reported during the study, four of which were considered not to be related to treatment with CZP. A total of three cases with fatal TEAEs were assessed as not related to CZP and the causes of death were reported as severe malignant lung neoplasm, severe throat cancer, and severe intracranial aneurysm. The causes of death for the remaining two patients were unknown.
Discussion
This is the first study to report real-world effectiveness and safety data of CZP in Canadian patients with RA. Overall, CZP was effective in the treatment of patients with RA, particularly with improvements in both work absenteeism and presenteeism, and no new safety signals were identified. A fifth of all patients achieved the primary objective of DAS28 < 2.6 at Week 104, and rapid improvements were observed in all additional study outcomes, when data were imputed using NRI. The proportion of patients achieving DAS28 < 2.6, or DAS28 < 3.2 increased from Week 12, and this proportion of patients was sustained to Week 104. Patientreported improvements in pain and fatigue were observed from Week 12 and mean scores were The proportion of patients in the FAS who completed the study to Week 104 was 42%, which is similar to the retention rate (36.2%) observed in the German FαST non-interventional study at Week 52. 17 While, the PROACTIVE non-interventional study in the United Kingdom and Ireland had a higher retention rate, with 68.5% of patients completing the study to Week 88. 18 Within the present study, it was observed that similar proportions of patients achieved DAS28 < 2.6 at Week 104, whether they had <2 years or ⩾2 years RA duration. Greater improvements in disease activity (DAS28) were observed in anti-TNF-naïve patients, when compared to patients with prior anti-TNF experience. In this study, >15% of patients had prior experience with ⩾2 anti-TNFs or other biologic agents. Prior experience with anti-TNFs is associated with lower response rates; the greater the number of antiTNFs previously used, the lower the associated response. 19, 20 Patients with moderate to high disease activity, who had only taken one prior anti-TNF, were more likely to achieve remission than patients with ⩾2 prior anti-TNF treatments. 20 Similarly, in the EXXELERATE trial, patients with one prior anti-TNF, showed a better DAS28(ESR) response as >50% of patients went on to achieve low disease activity [DAS28(ESR) ⩽ 3.2] from Week 12, compared to patients with >1 prior anti-TNF. 21 However, the REALISTIC study showed similar improvements in DAS28(CRP) and ACR20, 50 and 70 responses when patients were stratified by prior anti-TNF use; although a numerical trend for higher response rates was observed in anti-TNF-naïve patients. 22 Similarly, the results from the South Swedish Arthritis Treatment Group Register showed that first-time anti-TNF switchers had similar response rates to anti-TNF-naïve patients. 23 Patient-reported outcomes showed CZP treatment improved symptoms such as fatigue and arthritis associated pain through Week 104. These findings are consistent with short-term 12-week RCT data and longer-term data from the Corrona registry which showed that patients experienced improvements in pain and fatigue after anti-TNF treatment initiation. 14, 24, 25 These improvements were associated with better disease control, based on CDAI. 24 The improvements observed in household and workplace productivity are the first to be reported in a real-world Canadian setting and are consistent with RCTs where improvements in workplace and household productivity were maintained for the duration of the study. 14, 16 Similarly, clinically meaningful reductions in the rate of RA interference with workplace productivity have been observed in patients achieving HAQ-DI MCID. 14 We also report reductions in patient-reported pain and fatigue over 104 weeks, which are in line with observations from the RAPID-1 and REALISTIC trials. 26, 27 Observational data from the British Society of Rheumatology (BSR) Biologics Register also showed improvements in fatigue in patients treated with anti-TNFs (infliximab, etanercept and adalimumab); however, a different measure of fatigue was used than that in the present study. 28 Improvements in morning stiffness have previously been observed in patients treated with adalimumab (from the Corrona registry) and etanercept or infliximab compared with patients not receiving anti-TNF treatment, which complement the findings of the present study. 29, 30 No new safety signals were identified and the incidence of CZP-related TEAEs were in line with the known safety profile of CZP. 5, 6 The limitations of the study included the use of DAS28(CRP) as the preferred measure for the primary outcome as this was not validated in the most recent European League Against Rheumatism (EULAR) recommendations for the management of RA. 31 However, a comparison study showed that DAS28(CRP) and DAS28 (ESR) were both useful measures for assessing disease activity in patients with RA, 32 and the post-hoc analyses performed in this study indicated very similar results. Another limitation of the study was the observational design, which can result in inherent selection bias as the patients were not randomized into treatment and control groups, as in an RCT. This can result in the overestimation of treatment effects due to the lack of a control group. 33 Another limitation of the present study was that a high proportion of patients did not remain in the study to Week 104, and thus did not provide data for the primary endpoint of the study. Data were therefore imputed by NRI for the primary outcome; however, patients usually respond to CZP by Week 12 [DAS28(ESR)], after which their response is maintained, 34 these patients were likely to be those who did not respond to CZP.
Conclusion
Overall, the FαsT-CAN study demonstrated a long-term benefit of CZP treatment in patients with moderate to severe RA, in a Canadian practice setting. This is the first study to report patient-reported improvements in workplace and household productivity after 2 years of CZP treatment in a real-world Canadian practice setting, and these results are consistent with the results of previously published RCTs. 35 Similarly, rapid and sustained improvements in disease activity and patient-reported improvements in pain and fatigue were demonstrated.
Qualified researchers whose proposed use of the data has been approved by an independent review panel will be given access to anonymized individual participant data and redacted study documents. Additional information is available at www.clinicalstudydatarequest.com.
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